TLDR:
- Metsera, a weight-loss drug developer, has raised $290 million in funding led by ARCH Venture Partners.
- The company is developing injectable and oral drugs to treat obesity based on the GLP-1 mechanism and other biological targets.
Weight-loss drug developer Metsera has secured $290 million in funding, with biotech investor ARCH Venture Partners leading the investment round. The funding, which also includes participation from firms like SoftBank and Mubadala Capital, comes at a time when the weight-loss drug market is estimated to reach $100 billion by the end of the decade. Metsera, founded in 2022, is focusing on developing injectable and oral drugs for treating obesity through the GLP-1 mechanism and other biological targets. The company is aiming to compete with industry leaders like Novo Nordisk and Eli Lilly, who currently dominate the market with their popular new GLP-1 drugs. Metsera’s CEO, Clive Meanwell, highlighted the company’s goal to reach significant milestones in the next 12 months with the newly raised capital. The funding, raised through a syndicate of leading healthcare investors, is a combination of seed round and Series A financing. With experienced leaders and strategic partnerships, Metsera is poised to make a significant impact in the weight-loss drug development space.
